Skip to main content

Advertisement

SpringerLink
Log in
Menu
Find a journal Publish with us Track your research
Search
Cart
  1. Home
  2. Drugs & Aging
  3. Article

Influenza Vaccination in Older Patients

Immunogenicity, Epidemiology and Available Agents

  • Drug Therapy
  • Published: 17 October 2012
  • Volume 6, pages 368–387, (1995)
  • Cite this article
Download PDF
Drugs & Aging Aims and scope Submit manuscript
Influenza Vaccination in Older Patients
Download PDF
  • Horst Glathe1 &
  • Werner Lange1 

  • 127 Accesses

  • 18 Citations

  • Explore all metrics

Summary

Excess hospitalisation and deaths attributable to influenza virus infections often occur during epidemics and even in interepidemic periods. Influenza vaccines in current use are inactivated preparations that contain 15μg each of the most recently circulating influenza A (H3N2 and H1N1) and B viruses. At present, 3 types of inactivated influenza virus vaccines are available: (a) whole virus vaccines; (b) split virus vaccines; and (c) subunit vaccines. All 3 types are similarly immunogenic in primed patients.

Vaccine efficacy depends on a close antigenic match between the vaccine composition and the influenza strains circulating in the human population. The continuous antigenic drift of the viral membrane antigens (haemagglutinin and neuraminidase) necessitates an update of the vaccine composition each year according to the recommendations of the World Health Organization (WHO). Subunit and split virus vaccines cause fewer systemic reactions than whole virus vaccines. At present, live attenuated influenza virus vaccines are not licensed. In perspective, combined administration of live and inactivated vaccines seems to be advantageous.

Influenza vaccine is approximately 75% effective in reducing deaths in elderly and high risk persons. Several studies have shown that the antiviral agent amantadine is a useful adjunct to vaccination for preventing influenza A in institutional settings.

Currently, the proper use of inactivated vaccine according to the recommendations of public health authorities is the only way to reduce the annual influenza-associated medical and economic burden.

Article PDF

Download to read the full article text

Similar content being viewed by others

Influenza vaccination for elderly, vulnerable and high-risk subjects: a narrative review and expert opinion

Article Open access 27 October 2023

A post-marketing study to evaluate the safety and immunogenicity of a quadrivalent influenza split-virion vaccine in elderly people aged 60 years and older

Article Open access 15 September 2024

Influenza Vaccination in Older Adults: Recent Innovations and Practical Applications

Article 09 November 2018
Use our pre-submission checklist

Avoid common mistakes on your manuscript.

References

  1. Smith W, Andrewes CH, Laidlaw PP. A virus obtained from influenza patients. Lancet 1933; 2: 66–8

    Google Scholar 

  2. Francis T. A new type of virus from epidemic influenza. Science 1940; 92: 405–8

    PubMed  Google Scholar 

  3. Frank AL, Taber LH, Glezen WP, et al. Influenza B infections in the community and the family: the epidemics of 1976–1977 and 1979–1980 in Houston, Texas. Am J Epidemiol 1983; 118: 313–25

    PubMed  CAS  Google Scholar 

  4. Francis T, Quilligan II, Minuse E. Identification of another epidemic respiratory disease. Science 1950; 112: 495–7

    PubMed  Google Scholar 

  5. Shaw MW, Arden NH, Maassab HF. New aspects of influenza viruses. Clin Microbiol Rev 1992; 5: 74–92

    PubMed  CAS  Google Scholar 

  6. Hinshaw VS, Webster RG. The natural history of influenza A viruses. In: Beare AS, editor. Basic and applied influenza research. Boca Raton, Fla.: CRC Press 1992: 79–104

    Google Scholar 

  7. Ada GL, Jones PD. The immune response to influenza infection. Curr Top Microbiol Immunol 1986; 128: 4–10

    Google Scholar 

  8. Webster RG, Laver WG, Air GM. Molecular mechanism of variation in influenza viruses. Nature 1982; 296: 115–21

    PubMed  CAS  Google Scholar 

  9. Krystal M, Elliott RM, Benz EW, et al. Evolution of influenza A and B viruses: conservation of structural features in the hemagglutinin genes. Proc Nat Acad Sci USA 1982; 79: 4800–4

    PubMed  CAS  Google Scholar 

  10. Palese P, Tobita K, Ueda M. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 1974; 61: 397–410

    PubMed  CAS  Google Scholar 

  11. Schulman IL. Immunology of influenza. In: Kilbourne ED, editor. Influenza viruses and influenza. New York: Academic Press, 1975: 373–93

    Google Scholar 

  12. Couch RB, Kasel JA, Gerin JL. Induction of partial immunity by a neuraminidase-specific vaccine. J Infect Dis 1974; 129: 411–20

    PubMed  CAS  Google Scholar 

  13. Tite IP, Russell SM, Gongan D, et al. Antiviral immunity induced by recombinant nucleoprotein of influenza A virus I: characteristics and cross-reactivity of T cell responses. J Immunol 1988; 141: 3980–7

    PubMed  CAS  Google Scholar 

  14. Hay AI, Wolstenholme AJ, Skehel JJ, et al. Molecular basis of the specific anti-influenza action of amantadine. EMBO J 1985; 4: 3021–4

    PubMed  CAS  Google Scholar 

  15. Palese P, Kingsbury DW, editors. The genetics of influenza viruses. New York: Springer, 1983

    Google Scholar 

  16. Webster RG, Campbell CH, Granoff A. The in vivo production of ‘new’ influenza viruses. Virology 1971; 44: 317–28

    PubMed  CAS  Google Scholar 

  17. Scholtissek C, Burger H, Kistner O, et al. The nucleoprotein as a possible major factor in determining host specificity of influenza H3N2 virus. Virology 1985; 147: 287–94

    PubMed  CAS  Google Scholar 

  18. Hinshaw VS, Bean WJ, Webster RG, et al. The prevalence of influenza viruses in swine and the antigenic and genetic relatedness of influenza viruses from man and swine. Virology 1978; 84: 51–62

    PubMed  CAS  Google Scholar 

  19. Masurel N, Marine WM. Recycling of Asian and Hong Kong influenza A virus hemagglutinins in man. Am J Epidemiol 1973; 97: 44–9

    PubMed  CAS  Google Scholar 

  20. Scholtissek C, van Hoyningen V, Rott R. Genetic relatedness between the new 1977 epidemic strains (H1N1) of influenza and human influenza strains isolated between 1947 and 1957 Virology 1978; 89: 613–7

    CAS  Google Scholar 

  21. Schild GC, Oxford JS, de Jong C, et al. Evidence for host-cell selection of influenza virus antigenic variants. Nature 1983; 303: 706–9

    PubMed  CAS  Google Scholar 

  22. Robertson JS, Bootman JS, Newman R, et al. Structural changes in the haemagglutinin which accompany egg adaptation of an A (H1N1) virus. Virology 1987; 160: 31–7

    PubMed  CAS  Google Scholar 

  23. Katz JC, Naeve C, Webster RG. Host cell mediated variation in H3N2 influenza viruses. Virology 1987; 156: 386–95

    PubMed  CAS  Google Scholar 

  24. Potter CW, Oxford JS. Determinants of immunity to influenza in man. Br Med Bull 1979; 35: 69–75

    PubMed  CAS  Google Scholar 

  25. Davis JR, Grillis EA. Natural or vaccine-induced immunity as a predictor of immunity in the face of natural challenge with influenza virus. Epidemiol Inf 1989; 102: 325–33

    Google Scholar 

  26. Hobson D, Curry RL, Beare AS, et al. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hygeine 1972; 70: 767–72

    CAS  Google Scholar 

  27. Longini IM, Koopman JS, Haber M, et al. Statistical inference for infections diseases — risk specific household and community transmission parameters. Am J Epidemiol 1988; 128: 845–59

    PubMed  Google Scholar 

  28. Zuckerman MA, Wood J, Chakraverty P, et al. Serological responses in volunteers to inactivated trivalent subunit influenza vaccine: antibody reactivity with epidemic influenza A and B strains and evidence of a rapid immune response. J Med Virol 1991; 33: 133–7

    PubMed  CAS  Google Scholar 

  29. Pyhälä R, Alanko S, Forsten T, et al. Early kinetics of antibody response to inactivated influenza vaccine. Clin Diagn Virol 1993; 1: 271–8

    Google Scholar 

  30. Clark A, Potter CW, Jennings R, et al. A comparison of live and inactivated influenza A (H1N1) virus vaccines 2: long-term immunity. J Hyg Camb 1983; 90; 361–70

    PubMed  CAS  Google Scholar 

  31. Francis T, Davenport FM, Hennessy A. A serological recapitulation of human infection with different strains of influenza viruses. Trans Assoc Am Physicians 1953; 66: 231–9

    PubMed  Google Scholar 

  32. Davenport FM, Hennessy AV, Francis T. Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. J Exp Med 1953; 98: 641–7

    PubMed  CAS  Google Scholar 

  33. Webster RG. Original antigenic sin in ferrets: the responses to sequential infections with influenza viruses. J Immunol 1966; 97: 177–83

    PubMed  CAS  Google Scholar 

  34. Oxford JS, Haaheim LR, Slepushkin A, et al. Strain specifity of serum antibody to the haemagglutinin of influenza A (H3N2) viruses in children following immunization or natural infection. J Hyg Camb 1981; 86: 17–26

    PubMed  CAS  Google Scholar 

  35. Oxford JS, Schild GC, Potter CW, et al. The specificity of the anti-haemagglutinin antibody response induced in man by immunization and by natural infection. J Hyg Camb 1979; 82: 51–61

    PubMed  CAS  Google Scholar 

  36. Clements ML, Murphy BR. Development and persistence of systemic antibody responses in adults given live attenuated and inactivated influenza A virus vaccine. J Clin Microbiol 1986; 23: 66–72

    PubMed  CAS  Google Scholar 

  37. Zahradnik JM, Kasel JA, Martin RR, et al. Immune response in serum and respiratory tract secretions following vaccination with a live cold-recombinant (CR 35) and inactivated A/USSR/77 influenza virus vaccine. J Med Virol 1983; 11: 277–85

    PubMed  CAS  Google Scholar 

  38. Clements ML, Betts RF, Tierney EL, et al. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 1986; 24: 157–60

    PubMed  CAS  Google Scholar 

  39. McMichael AJ, Gotch FM, Noble GR, et al. Cytotoxic T cells to influenza. N Engl J Med 1983; 309: 13–7

    PubMed  CAS  Google Scholar 

  40. McMichael AJ, Gotch FM, Cullen P, et al. The human cytotoxic T cell response to influenza A vaccination. Clin Exp Immunol 1981; 43: 276–84

    PubMed  CAS  Google Scholar 

  41. Ennis FA, Yi-Hua Q, Schild GC. Antibody and cytotoxic T lymphocyte responses of humans to live and inactivated influenza vaccines. J Gen Virol 1982; 58: 273–81

    PubMed  CAS  Google Scholar 

  42. Wraith DC, Askonas BA. Induction of influenza A cross-reactive cytotoxic T cells by a nucleoprotein/haemagglutinin preparation. J Gen Virol 1985; 66: 1327–31

    PubMed  CAS  Google Scholar 

  43. Kuwano K, Scott M, Young JF, et al. HA2 subunit of influenza H1 and H2 subtype viruses induce a protective cross-reactive cytotoxic T lymphocyte response. J Immunol 1988; 140: 1264–8

    PubMed  CAS  Google Scholar 

  44. Thomas ML, Weigle WO. The cellular and subcellular basis of immunosenescence. Adv Immunol 1989; 46: 221–61

    Google Scholar 

  45. Huang JP, Pechere JC, Michel M. In vivo T cell activation, in vitro defective IL-2 secretion, and response to influenza in elderly women. J Immunol 1992; 148: 712–22

    Google Scholar 

  46. Denis F, Mounier M, Hessel L, et al. Hepatitis B vaccination in the elderly. J Infect Dis 1984; 149; 1019–23

    PubMed  CAS  Google Scholar 

  47. Hocart MJ, Mackenzie JS, Stewart GA. Serum IgG subclass responses of humans to inactivated and live influenza A vaccine compared to natural infection with influenza A. J Med Virol 1990; 30; 92–6

    PubMed  CAS  Google Scholar 

  48. Powers DC. Effect of age on immunoglobulin G subclass antibody responses to inactivated influenza vaccine. J Med Virol 1994; 43: 57–61

    PubMed  CAS  Google Scholar 

  49. Remarque EJ, van Beek WCA, Ligthardt GJ, et al. Improvement of the immunoglobulin subclass response to influenza vaccine in elderly nursing home residents by the use of high-dose vaccines. Vaccine 1993; 11: 649–54

    PubMed  CAS  Google Scholar 

  50. Burton D, Gregory L, Geheris R. Aspects of the molecular structure of IgG subclasses. Monographs in Allergy 1986; 19: 7–35

    PubMed  CAS  Google Scholar 

  51. Daynes RA, Aranes BA, Ershler WB, et al. Altered regulation of IL-6 production with normal aging: possible linkage to the age-associated decline in dihydroepiandrosterone and its sulfated derivative. J Immunol 1993; 150: 5219–30

    PubMed  CAS  Google Scholar 

  52. Powers DC, Belshe RB. Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine. J Infect Dis 1993; 167: 584–92

    PubMed  CAS  Google Scholar 

  53. Gorse GJ, Belshe RB. Enhancement of anti-influenza A virus cytotoxicity following influenza A vaccination in older, chronically ill patients. J Clin Microbiol 1990; 28; 2539–50

    PubMed  CAS  Google Scholar 

  54. Hemmes JH, Winkler KC, Kool SM. Virus survival as a seasonal factor in influenza and poliomyelitis. Nature 1960; 188: 430–1

    PubMed  CAS  Google Scholar 

  55. Ghendon Y. Influenza surveillance. Bull WHO 1991; 69: 509–15

    PubMed  CAS  Google Scholar 

  56. Longini IM, Koopman JS, Monto AS, et al. Estimating household and community transmission parameters for influenza. Am J Epidemiol 1982; 115: 736–51

    PubMed  Google Scholar 

  57. Monto AS, Kiomehr F. The Tecumseh study of respiratory illness, IX: occurrence of influenza in the community, 1966–1971. Am J Epidemiol 1975; 102: 553–63

    PubMed  CAS  Google Scholar 

  58. Immunization Practices Advisory Committee (ACIP). Prevention and control of influenza. Morb Mortal Wkly Rep 1992; 41: No. RR9

  59. Glezen WP. Serious morbidity and mortality associated with influenza epidemics. Epidemiol Rev 1982; 4: 25–42

    PubMed  CAS  Google Scholar 

  60. Collins SD, Frost WH, Gover M, et al. Mortality from influenza and pneumonia in 50 large cities of the United States, 1910–1929. Public Health Rep 1930; 45: 2277–329

    Google Scholar 

  61. Glathe H, Rasch G. Influenza surveillance in the former German Democratic Republic in the period 1969–1990 [in German]. Bundesgesundhbl 1992; 35: 500–6

    Google Scholar 

  62. Blackwelder WC, Alling DW, Stuart-Harris CH. Association of excess mortality from chronic nonspecific lung disease with epidemics of influenza. Am Rev Resp Dis 1982; 125: 511–6

    PubMed  CAS  Google Scholar 

  63. Baron RC, Dicker RC, Bussell KE, et al. Assessing trends in mortality in 121 U.S. cities, 1970-1979, from all causes and from pneumonia and from influenza. Public Health Rep 1988; 103: 120–8

    PubMed  CAS  Google Scholar 

  64. Choi K, Thacker SB. An evaluation of influenza mortality surveillance, 1962–1979, II: percentage of pneumonia and influenza deaths as an indicator of influenza activity. Am J Epidemiol 1981; 113: 227–35

    PubMed  CAS  Google Scholar 

  65. Lui K, Kendal AP. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am J Public Health 1987; 77: 712–6

    PubMed  CAS  Google Scholar 

  66. Cameron AS, Roder DM, Esterman AJ, et al. Mortality from influenza and allied infections in South Australia during 1968–1981. Med J Aust 1985; 142: 14–7

    PubMed  CAS  Google Scholar 

  67. McBean AM, Babish JD, Warren JL, et al. The effect of influenza epidemics on the hospitalization of persons 65 years and older. In: Hannoun C, Kendal AP, Klenk HD, et al., editors. Options for the control of influenza, II. Amsterdam: Elsevier Science 1993: 25–37

    Google Scholar 

  68. Sprenger MC, Mulder PGH, Beyer WEP. Impact of influenza on mortality in relation to age and underlying disease, 1967–1989. Int J Epidemiol 1993; 22: 234–40

    Google Scholar 

  69. Barker WH, Mullooly JP. Impact of influenza in a defined adult population. Am J Epidem 1980; 112: 798–813

    CAS  Google Scholar 

  70. Sprenger MIW, Diepersloot RJA, Beyer WEP, et al. Influenzarelated excess mortality in the Netherlands 1989/90. Lancet 1990: 382

  71. Curwen M, Dunnell K, Ashley J. Hidden influenza deaths. BMJ 1990; 300: 896

    Google Scholar 

  72. Stokes J, Chenoweth A, Waltz A, et al. J Clin Invest 1937; 16: 237–43

    PubMed  CAS  Google Scholar 

  73. Burnet FM. Influenza virus infections of the chick embryo by the amniotic route, I: general character of the infections. Aust J Exp Biol Med Sci 1940; 18: 353–60

    Google Scholar 

  74. Francis T, Salk J. A simplified procedure for the concentration and purification of influenza virus. Science 1942; 96: 494–500

    Google Scholar 

  75. Peck FB. Purified influenza virus vaccine: a study of viral reactivity and antigenicity. JAMA 1968; 206: 2277–83

    PubMed  Google Scholar 

  76. Reimer CB, Baker RS, Frank RM, et al. Purification of large quantities of influenza virus by density gradient centrifugation. J Virol 1967; 1: 1207–16

    PubMed  CAS  Google Scholar 

  77. Kilbourne ED, Schulman JL, Schild GC. Correlated studies of a recombinant influenza-virus vaccine, I: derivation of vaccine and characterization of virus and vaccine. J Infect Dis 1971; 124: 449–62

    PubMed  CAS  Google Scholar 

  78. Davenport FM. Antigenic enhancement of ether-extracted influenza virus vaccines by A1PO4. Proc Soc Exp Biol Med 1968; 127: 587–90

    PubMed  CAS  Google Scholar 

  79. Bachmayer H. Selective solubilization of haemagglutinin and neuraminidase from influenza viruses. Intervirology 1975; 5: 260–72

    PubMed  CAS  Google Scholar 

  80. Brady FM, Furminger JG. A surface antigen influenza vaccine. J Hyg Camb 1976; 77: 161–80

    PubMed  CAS  Google Scholar 

  81. Ennis FA, Dowdle WR, Barry DW, et al. Endotoxin content and clinical reactivity to influenza vaccines. J Biol Standard 1977; 5: 1651–72

    Google Scholar 

  82. Gross PA, Ennis FA, Gaerlan PF. A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole virus and split-product influenza vaccines in children. J Infect Dis 1977; 136: 623–32

    PubMed  CAS  Google Scholar 

  83. Nicholson KG, Harrison P, Potter CW, et al. Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine. J Biol Standard 1979; 7: 123–36

    CAS  Google Scholar 

  84. Laver WG, Webster RG. Preparation and immunogenicity of an influenza virus hemagglutinin and neuraminidase subunit vaccine. Virology 1970; 69: 511–22

    Google Scholar 

  85. Renfrey S, Watts A. Morphological and biochemical characterization of influenza vaccines available in the United Kingdom. Vaccine 1994; 12: 747–52

    PubMed  CAS  Google Scholar 

  86. Atkins E, Huang WC. Studies on the pathogenesis of fever with influenza virus. J Exp Med 1958; 127: 383–401

    Google Scholar 

  87. World Health Organization. Recommended composition of influenza virus vaccines for use in the 1994–1995 season. WHO Wkly Epidemiol Rec 1994; 8: 53–6

    Google Scholar 

  88. Kendal AP, Maassab HF, Alexandrova GI, et al. Development of cold-adapted-recombinant live, attenuated influenza A vaccines in the USA and USSR. Antiviral Res 1981; 1: 339–65

    Google Scholar 

  89. Maassab HF, DeBorde DC, Donabedian AM, et al. Prospects for influenza type B live attenuated vaccines. In: Kendal AP, Patriarca PA, editors. Options for the control of influenza, I. New York: Alan R. Liss, 1986: 271–86

    Google Scholar 

  90. Ghendon YZ, Klimov AI, Alexandrova GI, et al. Analysis of genome composition and reactogenicity of recombinants of cold-adapted and virulent virus strains. J Gen Virol 1981; 53: 215–24

    PubMed  CAS  Google Scholar 

  91. Murphy BR, Sly DL, Tierney EL, et al. Influenza A reassortant virus derived from avian and human influenza A viruses is attenuated and immunogenic in monkeys. Science 1982; 218: 1330–2

    PubMed  CAS  Google Scholar 

  92. World Health Organization. Requirements for influenza vaccine (inactivated). 1991. WHO Technical Report Series no. 814

  93. Arden NH, Patriarca PA, Kendal AP. Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes. In: Kendal AP, Patriarca PA, editors. Options for the control of influenza, I. New York: Alan R. Liss, 1986: 155–68

    Google Scholar 

  94. Strassburg MA, Greenland S, Sorvillo FJ, et al. Influenza in the elderly: report of an outbreak and a review of vaccine effectiveness reports. Vaccine 1986; 4: 38–42

    PubMed  CAS  Google Scholar 

  95. Serie C, Barme M, Hannoun C, et al. Effects of vaccination on an influenza epidemic in a geriatric hotel. Develop Biol Standard 1977; 39: 317–22

    CAS  Google Scholar 

  96. Aymard M, Bentejac MC, Larbaigt G, et al. Efficacy of the antiinfluenza A vaccination during epidemics due to A/Vic/3/75 and A/Texas/1/77 viruses. Develop Biol Standard 1979: 43: 231–9

    CAS  Google Scholar 

  97. Patriarca PA, Weber JA, Parker RA, et al. Efficacy of influenza vaccine in nursing homes: reduction in illness and complications during an influenza A (H3N2) epidemic. JAMA 1985; 253: 1136–39

    PubMed  CAS  Google Scholar 

  98. Meiklejohn G. Viral respiratory disease at Lowry Air Force Base in Denver, 1952–82. J Inf Dis 1983; 148: 775–84

    CAS  Google Scholar 

  99. Gross PA, Quinnan GV, Rodstein M, et al. Association of influenza immunization with reduction in mortality in an elderly population. Arch Intern Med 1988; 148: 562–5

    PubMed  CAS  Google Scholar 

  100. Saah AF, Nenfield R, Rodstein M, et al. Influenza vaccine and pneumonia mortality in a nursing home population. Arch Intern Med 1986; 146: 2353–7

    PubMed  CAS  Google Scholar 

  101. Odelin MF, Pozetto B, Aymard M, et al. Role of influenza vaccination in the elderly during an epidemic of A/H1N1 virus in 1988–1989: clinical and serological data. Gerontology 1993; 39: 109–16

    PubMed  CAS  Google Scholar 

  102. Arden N, Bidol S, Ohmit S, et al. Effect of nursing home size and influenza vaccination rates on the risk of institutional outbreaks during an influenza A (H3N2) epidemic. In: Hannoun C, Kendal AP, Klenk HD, et al., editors. Options for the control of influenza, II. Amsterdam: Elsevier Science, 1993: 161–5

    Google Scholar 

  103. Foster DA, Talsma AN, Furumoto-Dawson A, et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 1992; 136: 296–307

    PubMed  CAS  Google Scholar 

  104. Ruben FL. Who needs influenza vaccine? In: Kendal AP, Patriarca PA, editors. Options for the control of influenza, I. New York: Alan R. Liss, 1986: 139–54

    Google Scholar 

  105. Barker WH, Mullooly JP. Influenza vaccination of elderly persons: reduction in pneumonia and influenza hospitalizations and deaths. JAMA 1980; 244: 2547–9

    PubMed  CAS  Google Scholar 

  106. Barker WH, Mullooly JP. Effectiveness of inactivated influenza vaccine among non-institutionalized elderly persons. In: Kendal AP, Patriarca PA, editors. Options for the control influenza, I. New York: Alan R. Liss 1986: 169–82

    Google Scholar 

  107. Six HR, Kasel JA. Assessment of genetic relatedness among haemagglutinins of type A influenza viruses by competition radioimmunoassay. Virology 1979; 96: 588–96

    PubMed  CAS  Google Scholar 

  108. Nichol KL, Margolis KL, Wuorenma J, et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 333: 778–84

    Google Scholar 

  109. Monto AS. Influenza vaccines for the elderly. N Engl J Med 1994; 333: 807–8

    Google Scholar 

  110. Fedson DS, Wajda A, Nicol JP, et al. Clinical effectiveness of influenza vaccination in Manitoba. JAMA 1993; 270: 1956–61

    PubMed  CAS  Google Scholar 

  111. Govaert TM, Thijs CN, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals: a randomised doubleblind placebo-controlled-trial. JAMA 1994; 272: 1661–5

    PubMed  CAS  Google Scholar 

  112. Strikas R, Cook P, Kuller L, et al. Case control study in Ohio and Pennsylvania on prevention of hospitalization by influenza vaccination. In: Hannoun C, Kendal AP, Klenk HD, et al., editors. Options for the control of influenza, II. Amsterdam: Elsevier Science, 1993: 153–60

    Google Scholar 

  113. Couch RB, Kasel JA, Glezen WP, et al. Influenza: its control in persons and populations. J Infect Dis 1986; 153: 431–40

    PubMed  CAS  Google Scholar 

  114. Beyer WEP, Palache AM, Beljet M, et al. Antibody induction by influenza vaccines in the elderly: a review of the literature. Vaccine 1989; 7: 385–95

    PubMed  CAS  Google Scholar 

  115. Bigl S, Glathe H, Grosche A. Zum Problem der altersabhängigen Immunantwort nach Influenzaschutzimpfung. Z Klin Med 1992; 47: 203–6

    Google Scholar 

  116. Gross PA, Quinnan GV, Weksler ME, et al. Relation of chronic disease and immune response to influenza vaccine in the elderly. Vaccine 1989; 7: 303–8

    PubMed  CAS  Google Scholar 

  117. Brown AE. Influenza and pneumococcal immunization of patients with neoplastic diseases. Schweiz med Wschr 1983; 113 Suppl. 14: 30–4

    Google Scholar 

  118. Keitel WA, Cate TR, Couch RB, Efficacy of sequential annual vaccination with inactivated influenza virus vaccine. Am J Epidemiol 1988; 127: 353–64

    PubMed  CAS  Google Scholar 

  119. Brandriss MW, Schlesinger JJ, Douglas RG. Responses of elderly subjects to a new subunit influenza vaccine. J Infect Dis 1982; 145: 277

    PubMed  CAS  Google Scholar 

  120. McElhaney JE, Meneilly GS, Lechelt KE. Antibody response to whole-virus and split-virus influenza vaccines in successful ageing. Vaccine 1993; 11: 1055–60

    PubMed  CAS  Google Scholar 

  121. McElhaney JE, Meneilly GS, Lechelt KE, et al. Split-virus influenza vaccines: do they provide adequate immunity in the elderly? J Gerontol 1994; 49(2): M37–43

    PubMed  CAS  Google Scholar 

  122. Powers DC. Increased immunogenicity of inactivated influenza vaccine containing purified surface-antigen compared with whole virus in elderly women. Clin Diagn Lab Immunol 1994; 1: 16–20

    PubMed  CAS  Google Scholar 

  123. Powers DC, Belshe RB. Vaccine-induced antibodies to heterologous influenza A H1N1 viruses: effects of aging and ‘original antigenic sin’. J Inf Dis 1994; 169: 1125–9

    CAS  Google Scholar 

  124. Gross PA, Quinnan GV, Weksler ME, et al. Immunization of elderly people with high doses of influenza vaccine. J Am Geriatr Soc 1988; 36: 209–12

    PubMed  CAS  Google Scholar 

  125. Sullivan KM, Monto AS, Foster DA. Antibody response to inactivated influenza vaccines of various antigenic concentrations. J Infect Dis 1990; 161: 333–5

    PubMed  CAS  Google Scholar 

  126. Wood JM, Schild GC, Newman RW, et al. Application of an improved single-radial-immunodiffusion technique for the assay of haemagglutinin antigen content of whole virus and subunit influenza vaccines. Develop Biol Stand 1977; 39: 193–200

    CAS  Google Scholar 

  127. Arden NH, Patriarca PA, Lui KJ, et al. Safety and immunogenicity of 45 μg supplemental dose of inactivated split-virus influenza B vaccine in the elderly. J Infect Dis 1986; 153: 805–6

    PubMed  CAS  Google Scholar 

  128. Goodeve A, Potter CW, Clark A, et al. A graded-dose study of inactivated surface antigen influenza B vaccine in volunteers: reactogenicity, antibody response and protection to challenge virus infection. J Hyg Camb 1983; 90: 107–15

    PubMed  CAS  Google Scholar 

  129. Palache AM, Beyer WEP, Lüchters G, et al. Influenza vaccines: the effect of vaccine dose on antibody response in primed populations during the ongoing interopandemic period — review of the literature. Vaccine 1993; 11: 892–908

    PubMed  CAS  Google Scholar 

  130. Palache AM, Beyer WEP, Sprenger MJW, et al. Antibody response after influenza immunization with various vaccine doses: a double blind, placebo-controlled, multi-centre, doseresponse study in elderly nursing-home residents and young volunteers. Vaccine 1993; 11: 3–9

    PubMed  CAS  Google Scholar 

  131. Glathe M, Bigl S, Grosche A. Comparison of humoral immune responses to trivalent influenza split vaccine in young, middle aged, and elderly people. Vaccine 1993; 11: 702–5

    PubMed  CAS  Google Scholar 

  132. Levine M, Beattie BL, McLean DM. Comparison of one- and two-dose regimes of influenza vaccine for elderly men. Can Med Ass J 1987; 137: 722–6

    CAS  Google Scholar 

  133. Gross PA, Weksler ME, Quinnan GV, et al. Immunization of elderly people with two doses of influenza vaccine. J Clin Microbiol 1987; 25; 1763–5

    PubMed  CAS  Google Scholar 

  134. Mbawuike JN, Wyde PR, Anderson PM. Enhancement of the protective efficacy of inactivated influenza A virus vaccine in aged mice by IL-2 liposomes. Vaccine 1990; 8: 347–52

    PubMed  CAS  Google Scholar 

  135. Tamura SI, Samegai Y, Kurata H, et al. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit. Vaccine 1988; 6: 409–12

    PubMed  CAS  Google Scholar 

  136. Nerome K, Yoshioda Y, Ishida M, et al. Development of a new type of influenza subunit vaccine made by muramyl-dipeptide-liposome: enhancement of humoral and cellular immune response. Vaccine 1990; 8: 503–9

    PubMed  CAS  Google Scholar 

  137. Morein B. The ISCOM antigen-presenting system. Nature 1988; 332: 287–8

    PubMed  CAS  Google Scholar 

  138. Heilman C. New approaches to vaccine delivery. In: Hannoun C, Kendal AP, Klenk HD, et al.,editors. Options for the control of influenza, II. Amsterdam: Elsevier Science, 1993: 389–90

    Google Scholar 

  139. Glück R, Mischler R, Finkel B, et al. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 1993; 344: 160–63

    Google Scholar 

  140. Betts RF, Treanor JJ, Mattison HR, et al. Evaluation of inactivated influenza vaccine with or without supplemental live attenuated cold-adapted vaccine in high-risk elderly. In: Hannoun C, Kendal AP, Klenk HD, et al., editors. Options for the control of influenza, II. Amsterdam: Elsevier Science, 1993: 373–8

    Google Scholar 

  141. Treanor II, Mattison HR, Dumyati G, et al. Protective efficacy of combined live intranasal and inactivated Influenza A virus vaccines in the elderly. Ann Intern Med 1992; 117: 625–33

    PubMed  CAS  Google Scholar 

  142. Powers DC, Sears SD, Murphy BR, et al. Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines. J Clin Microbiol 1989; 27: 2666–73

    PubMed  CAS  Google Scholar 

  143. Treanor JJ, Betts RF. Use of live vaccine in the elderly. In: Hannoun C, Kendal AP, Klenk HD, et al., editors. Options for the control of influenza, II. Amsterdam: Elsevier Science, 1993: 381–6

    Google Scholar 

  144. Edwards KM, Dupont WD, Westlich MK, et al. A randomized trial of cold-adapted and inactivated vaccines in the prevention of influenza A disease. J Infect Dis 1993; 169: 68–76

    Google Scholar 

  145. Powers DC, Fries LF, Murphy BR, et al. In elderly persons live attenuated influenza A vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory. J Clin Microbiol 1991; 29: 498–505

    PubMed  CAS  Google Scholar 

  146. D’Alesio DJ, Cox PM, Dick EC. Failure of inactivated influenza vaccine to protect an aged population. JAMA 1969; 210: 485–9

    Google Scholar 

  147. Keren G, Seger S, Morag A, et al. Failure of influenza vaccination in the aged. J Med Virol 1988; 25: 85–9

    PubMed  CAS  Google Scholar 

  148. Schröder HE, Künzel W, Glathe H, et al. Immunogenicity and reactogenicity of a trivalent influenza virus split vaccine [in German]. Bundesgesundhbl 1993; 37: 449–53

    Google Scholar 

  149. Govaert TM, Sprenger MJW, Dirwent GJ, et al. Immune response to influenza vaccination of elderly people: a randomised double-blind placebo-controlled trial. Vaccine 1994; 12: 1185–9

    PubMed  CAS  Google Scholar 

  150. Palache AM. Influenza subunit vaccine — ten years experience. Eur J Clin Res 1992; 3: 117–38

    Google Scholar 

  151. Scheifele DW, Björnson G, Johnston J. Evaluation of adverse effects after influenza vaccination in hospital personnel. Can Med Assoc J 1990; 142(2) 127–30

    CAS  Google Scholar 

  152. Chernesky M, O’Neill DO, Pickard L, et al. Immunogenicity and adverse reactions of influenza vaccination in elderly patients given acetaminophen or placebo. Clin Diagn Virol 1993; 1: 129–36

    PubMed  CAS  Google Scholar 

  153. Govaert ME, Dinant GJ, Aretz K. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. BMJ 1993; 307: 988–90

    PubMed  CAS  Google Scholar 

  154. Margolis KL, Nichol KL, Poland GA, et al. Frequency of adverse reactions to influenza vaccine in the elderly. JAMA 1990; 264: 1139–41

    PubMed  CAS  Google Scholar 

  155. Hinman AR, Schonberger LB, Retaillian HF. Influenza immunization: the U.S. experience. Develop Biol Stand 1979; 43: 223–30

    CAS  Google Scholar 

  156. Ganguly R, Schier S, Vargas L, et al. Reasons for non-immunization against influenza in the aged. J Am Geriatr Soc 1989; 37: 387–9

    PubMed  CAS  Google Scholar 

  157. Palache AM, van der Velden JW. Influenza vaccination in asthma. Lancet 1992; 339: 741

    PubMed  CAS  Google Scholar 

  158. Murphy KR, Strunh RC. Safe administration of influenza vaccine in asthmatic children sensitive to egg proteins. J Pediatr 1985; 106: 931–3

    PubMed  CAS  Google Scholar 

  159. Renton KW, Gray JD, Hall RI. Decreased elimination of theophylline after influenza vaccination. Can Med J 1980; 123: 288–90

    CAS  Google Scholar 

  160. Kramer P, McClain CJ. Depression of aminopyrine metabolism by influenza vaccination. N Engl J Med 1981; 305: 1262–4

    PubMed  CAS  Google Scholar 

  161. Levine M, Jones MW, Gribble M. Increased serum phenytoin concentration following influenza vaccination. Clin Pharm 1984; 3: 505–9

    PubMed  CAS  Google Scholar 

  162. Patriarca PA, Kendal AP, Stricof RL, et al. Influenza vaccination and warfarin or theophylline toxicity in nursing-home residents. N Engl J Med 1983; 308: 1601–2

    PubMed  CAS  Google Scholar 

  163. Grabowski N, May JJ, Pratt DS, et al. The effect of split virus influenza vaccination on theophylline pharmacokinetics. Am Rev Respir Dis 1985; 131: 934–8

    PubMed  CAS  Google Scholar 

  164. Ehrengut W, Allerdist H. Über neurologische Komplikationen nach der Influenzaschutzimpfung. Münch Med Wschr 1977; 119: 705–10

    CAS  Google Scholar 

  165. Roscelli JD, Bass JW, Pang L. Guillan-Barre syndrome and influenza vaccination in the US army, 1980–1988. Am J Epidem 1991; 133: 952–5

    CAS  Google Scholar 

  166. Safranek T, Lawrence DN, Kurland LT. Reassessment of the association between Guillan-Barre’ syndrome and receipt of swine influenza vaccine in 1976–1977 results of a two state study. Am J Epidem 1991; 133: 930–51

    Google Scholar 

  167. Chapman LE. Amantadine use for control of institutional influenza A. In: Hannoun C, Kendal AP, Klenk HD, et al., editors. Options for the control of influenza, II. Amsterdam: Elsevier Science, 1993: 343–8

    Google Scholar 

  168. Mostow SR. Prevention, management, and control of influenza: role of amantadine. Am J Med 1987; 82 Suppl. 6A: 35–41

    PubMed  CAS  Google Scholar 

  169. Dolin R, Reichman RC, Madore HP, et al. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 1982; 307: 580–3

    PubMed  CAS  Google Scholar 

  170. Kobayashi JM. Control of influenza A outbreaks in nursing homes: amantadine as a adjunct to vaccine: 1989–1990. Morb Mortal Wkly Rep 1991; 40: 841–4

    Google Scholar 

  171. Mast EE, Harmon MW, Gravenstein S, et al. Emergence and possible transmission of amantadine resistant viruses during nursing home outbreaks of influenza A (H3N2). Am J Epidemiol 1991; 13: 988–97

    Google Scholar 

  172. Horadam VW, Sharp JG, Smilack J, et al. Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. Ann Intern Med 1981; 93: 454–8

    Google Scholar 

  173. Belshe RB, Burk B, Cerruti RL, et al. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J Infect Dis 1989; 159: 430–5

    PubMed  CAS  Google Scholar 

  174. Fedson DS. Overview of national approaches to influenza vaccination. In: Hannoun C, Kendal AP, Klenk HD, et al., editors. Options for the control of influenza, II. Amsterdam: Elsevier Science, 1993: 393–6

    Google Scholar 

  175. Fedson DS, Clinical practice and public policy for influenza and pneumococcal vaccination of the elderly. Clin Geriatr Med 1992; 8: 183–99

    PubMed  CAS  Google Scholar 

  176. Williams WW, Hickson MA, Kane MA, et al. Immunization policies and vaccine coverage among adults: the risk for missed opportunities. Ann Intern Med 1988; 108: 616–25

    PubMed  CAS  Google Scholar 

  177. Margolis KL, Lofgren RP, Korn JE. Organizational strategies to improve influenza vaccine delivery: a standing order in a general medical clinic. Arch Intern Med 1988; 148: 2205–7

    PubMed  CAS  Google Scholar 

  178. Weingarten S, Riedinger M, Bolton LB. Barriers to influenza vaccine acceptance. A survey of physicians and nurses. Am J Infect Control 1989; 17: 202–7

    PubMed  CAS  Google Scholar 

  179. Nichol KL, Korn JE, Margolis KL, et al. Achieving the national health objective for influenza immunization: success of an institution-wide vaccination programm. Am J Med 1990; 89: 156–60

    PubMed  CAS  Google Scholar 

  180. von Itzstein M, Wu WY, Kok GB, et al. Rational design of sialidase-based inhibitors of influenza virus replication. Nature 1993; 363: 418–23

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Robert-Koch-Institute, Berlin, Germany

    Horst Glathe & Werner Lange

Authors
  1. Horst Glathe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Werner Lange
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Glathe, H., Lange, W. Influenza Vaccination in Older Patients. Drugs & Aging 6, 368–387 (1995). https://doi.org/10.2165/00002512-199506050-00004

Download citation

  • Published: 17 October 2012

  • Issue Date: May 1995

  • DOI: https://doi.org/10.2165/00002512-199506050-00004

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Keywords

  • Influenza
  • Influenza Virus
  • Virus Vaccine
  • Influenza Vaccine
  • Influenza Vaccination
Use our pre-submission checklist

Avoid common mistakes on your manuscript.

Advertisement

Search

Navigation

  • Find a journal
  • Publish with us
  • Track your research

Discover content

  • Journals A-Z
  • Books A-Z

Publish with us

  • Journal finder
  • Publish your research
  • Open access publishing

Products and services

  • Our products
  • Librarians
  • Societies
  • Partners and advertisers

Our imprints

  • Springer
  • Nature Portfolio
  • BMC
  • Palgrave Macmillan
  • Apress
  • Your US state privacy rights
  • Accessibility statement
  • Terms and conditions
  • Privacy policy
  • Help and support
  • Cancel contracts here

98.84.18.52

Not affiliated

Springer Nature

© 2024 Springer Nature